Cargando…
Cardioprotective Effects of a Novel Hydrogen Sulfide Agent–Controlled Release Formulation of S-Propargyl-Cysteine on Heart Failure Rats and Molecular Mechanisms
OBJECTIVE: Heart failure (HF) is one of the most serious diseases worldwide. S-propargyl-cysteine (SPRC), a novel modulator of endogenous hydrogen sulfide, is proved to be able to protect against acute myocardial ischemia. In order to produce more stable and sustainable hydrogen sulfide, we used con...
Autores principales: | Huang, Chengrong, Kan, Juntao, Liu, Xu, Ma, Fenfen, Tran, Ba Hieu, Zou, Yunzeng, Wang, Shujun, Zhu, Yi Zhun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3706411/ https://www.ncbi.nlm.nih.gov/pubmed/23874913 http://dx.doi.org/10.1371/journal.pone.0069205 |
Ejemplares similares
-
Cardioprotective effects and pharmacokinetic properties of a controlled release formulation of a novel hydrogen sulfide donor in rats with acute myocardial infarction
por: Tran, Ba Hieu, et al.
Publicado: (2015) -
A Novel Liposomal S-Propargyl-Cysteine: A Sustained Release of Hydrogen Sulfide Reducing Myocardial Fibrosis via TGF-β1/Smad Pathway
por: Tran, Ba Hieu, et al.
Publicado: (2019) -
S-Propargyl-Cysteine, a Novel Hydrogen Sulfide Donor, Inhibits Inflammatory Hepcidin and Relieves Anemia of Inflammation by Inhibiting IL-6/STAT3 Pathway
por: Wang, Minjun, et al.
Publicado: (2016) -
Gp130-mediated STAT3 activation by S-propargyl-cysteine, an endogenous hydrogen sulfide initiator, prevents doxorubicin-induced cardiotoxicity
por: Wu, J, et al.
Publicado: (2016) -
Mechanism of Growth Regulation of Yeast Involving Hydrogen Sulfide From S-Propargyl-Cysteine Catalyzed by Cystathionine-γ-Lyase
por: Gu, Zhongkai, et al.
Publicado: (2021)